HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Rating of “Hold” by Brokerages

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has been assigned an average rating of “Hold” from the six ratings firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $14.8667.

A number of analysts have recently issued reports on the stock. The Goldman Sachs Group cut their target price on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Thursday, July 23rd. Bank of America decreased their price target on shares of HUTCHMED from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Morgan Stanley set a $13.60 price target on shares of HUTCHMED in a report on Thursday, May 28th. Weiss Ratings downgraded shares of HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a research report on Friday, July 31st. Finally, Wall Street Zen upgraded HUTCHMED from a “hold” rating to a “buy” rating in a report on Saturday, August 8th.

Institutional Trading of HUTCHMED

Several hedge funds have recently added to or reduced their stakes in the company. Ameriprise Financial Inc. grew its holdings in HUTCHMED by 4.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after buying an additional 698 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of HUTCHMED by 17.3% during the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after buying an additional 3,035 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of HUTCHMED by 34.2% during the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock worth $342,000 after buying an additional 5,538 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in shares of HUTCHMED in the first quarter valued at about $365,000. Finally, BNP Paribas Financial Markets boosted its position in shares of HUTCHMED by 19.7% in the second quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock valued at $377,000 after acquiring an additional 4,116 shares during the period. 8.82% of the stock is owned by institutional investors and hedge funds.

HUTCHMED Price Performance

HCM stock opened at $12.38 on Monday. HUTCHMED has a 1-year low of $9.77 and a 1-year high of $18.30. The business’s 50 day simple moving average is $11.50 and its 200 day simple moving average is $12.79. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.64 and a quick ratio of 5.50.

HUTCHMED (NASDAQ:HCM) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.09). The business had revenue of $139.14 million during the quarter, compared to analyst estimates of $304.16 million. As a group, analysts expect that HUTCHMED will post 0.23 EPS for the current fiscal year.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.